Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT06718400

Vascularised Sentinel Skin Flaps to Predict Rejection in Intestinal Transplantation

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
The Cleveland Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This pilot study aims to validate the use of vascularised donor-derived sentinel skin flaps for diagnosing and monitoring rejection in intestinal transplantation

Detailed description

Intestinal transplantation is the current treatment option for patients with irreversible intestinal failure that has not responded to other methods of treatment. Whilst the majority of patients that have an intestinal transplant will obtain good graft function over many years, some patients suffer from reduced function of their new intestine following transplantation that can progress to the transplant failing completely. Acute rejection may be the most common cause of transplant failure. Currently, there is not an effective way of monitoring the intestine that can detect rejection before irreversible damage occurs. If there is a more sensitive way of continuously monitoring the intestine transplant for rejection then issues could be earlier detected and early treatment could prevent permanent damage to the transplant. The reason for this study is to assess a new technique that has been developed to detect early rejection in intestinal transplantation. The name of this technique is called a 'sentinel skin flap' and involves transplanting a patch of forearm skin from the donor at the same time as the intestine

Conditions

Interventions

TypeNameDescription
PROCEDURESentinel Skin FlapWilling participants who will be receiving an intestinal transplantation will receive a sentinel skin flap on their forearm from the same donor

Timeline

Start date
2023-10-01
Primary completion
2023-10-01
Completion
2023-10-01
First posted
2024-12-05
Last updated
2024-12-05

Source: ClinicalTrials.gov record NCT06718400. Inclusion in this directory is not an endorsement.